Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania

Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania

The introduction in clinical practice of selective cyclin-dependent kinase (CDK) 4/6 inhibitors improves the outcome of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). In Romania, the three available CDK 4/6 inhibi...

Full description

Bibliographic Details
Main Authors: Andreea-Iuliana Miron, Alexandra-Valentina Anghel, Andrei-Alexandru Barnonschi, Ruxandra Mitre, Horia-Dan Liscu, Estera Găinariu, Raluca Pătru, Simona Coniac
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Diagnostics
Subjects:
CDK 4/6 inhibitors
metastatic breast cancer HR+
progression-free survival
real-world data
Online Access:https://www.mdpi.com/2075-4418/13/11/1938

Internet

https://www.mdpi.com/2075-4418/13/11/1938

Similar Items